Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T14:01:15.608Z Has data issue: false hasContentIssue false

High frequency of clinical conditions commonly associated with mitochondrial disorders in schizophrenia

Published online by Cambridge University Press:  24 April 2020

Yolanda Alonso
Affiliation:
University Hospital Institut Pere Mata, Health Research Institute Pere Virgili (IISPV), Rovira i Virgili University (URV), Reus, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
Alba Valiente-Pallejà
Affiliation:
University Hospital Institut Pere Mata, Health Research Institute Pere Virgili (IISPV), Rovira i Virgili University (URV), Reus, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
Begoña Verge
Affiliation:
University Hospital Institut Pere Mata, Health Research Institute Pere Virgili (IISPV), Rovira i Virgili University (URV), Reus, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
Elisabet Vilella
Affiliation:
University Hospital Institut Pere Mata, Health Research Institute Pere Virgili (IISPV), Rovira i Virgili University (URV), Reus, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
Lourdes Martorell*
Affiliation:
University Hospital Institut Pere Mata, Health Research Institute Pere Virgili (IISPV), Rovira i Virgili University (URV), Reus, Spain Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain
*
Author for correspondence: Lourdes Martorell, Email: [email protected]

Abstract

Objective:

It has been hypothesised that neuropsychiatric symptoms, including psychosis, can be the result of a milder brain bioenergetic defect produced by mitochondrial dysfunction; however, mitochondrial dysfunction can be present in other organs or systems. The aim of the study was to investigate whether clinical conditions associated with mitochondrial disorders (CAMDs) were frequently present in schizophrenia.

Methods:

A previously used questionnaire regarding the CAMDs was administered to patients and controls in a direct interview with a trained psychiatrist. The frequencies of CAMDs in 164 patients with schizophrenia were compared to those in 156 age- and sex-matched controls.

Results:

Severe fatigue, seizures, constipation and diabetes were significantly more frequent in patients with schizophrenia than in control subjects and apparently not related to pharmacological treatment.

Conclusion:

The results of the present study suggest that multi-systemic mitochondrial dysfunction may be an underlying mechanism involved in schizophrenia.

Type
Short Communication
Copyright
© Scandinavian College of Neuropsychopharmacology 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (5th Edition). Arlington, VA: American Psychiatric Publishing.Google Scholar
Agrawal, N and Mula, M (2019) Treatment of psychoses in patients with epilepsy: An update. Therapeutic Advances in Psychopharmacology 9, 2045125319862968.CrossRefGoogle ScholarPubMed
Castillo, RI, Rojo, LE, Henriquez-Henriquez, M, Silva, H, Maturana, A, Villar, MJ, Fuentes, M and Gaspar, PA (2016) From molecules to the clinic: Linking schizophrenia and metabolic syndrome through sphingolipids metabolism. Frontiers in Neuroscience 10, 488. eCollection 2016.CrossRefGoogle ScholarPubMed
Chinnery, PF (2014) Mitochondrial disorders overview. In Adam, MP, Ardinger, HH, Pagon, RA, Wallace, SE, Bean, LJH, Stephens, K and Amemiya, A (eds.), GeneReviews® [Internet]. Seattle (WA): University of Washington [updated 4 Aug. 2014]. http://www.ncbi.nlm.nih.gov/books/NBK1224/Google Scholar
Chow, J, Rahman, J, Achermann, JC, Dattani, MT and Rahman, S (2017) Mitochondrial disease and endocrine dysfunction. Nature Reviews. Endocrinology 13, 92104.CrossRefGoogle ScholarPubMed
Crump, C, Winkleby, MA, Sundquist, K and Sundquist, J (2013) Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study. American Journal of Psychiatry 170, 324333.CrossRefGoogle ScholarPubMed
Davis, J, Eyre, H, Jacka, FN, Dodd, S, Dean, O, McEwen, S, Debnath, M, McGrath, J, Maes, M, Amminger, P, McGorry, PD, Pantelis, C and Berk, M (2016) A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience and Biobehavioral Reviews 65, 185194.CrossRefGoogle ScholarPubMed
De Hert, M, Hudyana, H, Dockx, L, Bernagie, C, Sweers, K, Tack, J, Leucht, S and Peuskens, J (2011) Second-generation antipsychotics and constipation: A review of the literature. European Psychiatry 26, 3444.CrossRefGoogle ScholarPubMed
Dieset, I, Andreassen, OA and Haukvik, UK (2016) Somatic comorbidity in schizophrenia: some possible biological mechanisms across the life span. Schizophrenia Bulletin 42, 13161319.CrossRefGoogle ScholarPubMed
Every-Palmer, S, Newton-Howes, G and Clarke, MJ (2017) Pharmacological treatment for antipsychotic-related constipation. The Cochrane Database of Systematic Review 1, CD011128.Google ScholarPubMed
Every-Palmer, S, Inns, SJ, Grant, E and Ellis, PM (2019). Effects of clozapine on the gut: Cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs 33, 8191.10.1007/s40263-018-0587-4CrossRefGoogle ScholarPubMed
Finsterer, J and Frank, M (2017) Gastrointestinal manifestations of mitochondrial disorders: A systematic review. Therapeutic Advances in Gastroenterology 10, 142154.10.1177/1756283X16666806CrossRefGoogle ScholarPubMed
Hüfner, K, Frajo-Apor, B and Hofer, A (2015) Neurology issues in schizophrenia. Current Psychiatry Reports 17, 32.CrossRefGoogle Scholar
Konradi, C and Öngür, D (2017) Role of mitochondria and energy metabolism in schizophrenia and psychotic disorders. Schizophrenia Research 187, 12.CrossRefGoogle ScholarPubMed
Las, G, Oliveira, MF and Shirihai, OS (2020) Emerging roles of β-cell mitochondria in type-2-diabetes. Molecular Aspects of Medicine 71, 100843.CrossRefGoogle ScholarPubMed
Laursen, TM, Nordentoft, M and Mortensen, PB (2014) Excess early mortality in schizophrenia. Annual Review of Clinical Psychology 10, 425–48.CrossRefGoogle Scholar
Maguire, M, Singh, J and Marson, A (2018) Epilepsy and psychosis: A practical approach. Practical Neurology 18, 106114.CrossRefGoogle ScholarPubMed
Makrecka-Kuka, M, Liepinsh, E, Murray, AJ, Lemieux, H, Dambrova, M, Tepp, K, Puurand, M, Käämbre, T, Han, WH, de Goede, P, O’Brien, KA, Turan, B, Tuncay, E, Olgar, Y, Rolo, AP, Palmeira, CM, Boardman, NT, Wüst, RCI and Larsen, TS (2019) Altered mitochondrial metabolism in the insulin-resistant heart. Acta Physiologica 16, e13430.Google Scholar
Nasrallah, HA (2005) An overview of common medical comorbidities in patients with schizophrenia. Journal of Clinical Psychiatry 66, 34.Google ScholarPubMed
Nguyen, TT, Kosciolek, T, Eyler, LT, Knight, R and Jeste, DV (2018) Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. Journal of Psychiatric Research 99, 5061.CrossRefGoogle ScholarPubMed
Obara, K, Horiguchi, S, Shimada, T, Ikarashi, T, Yamaki, F, Matsuo, K, Yoshio, T and Tanaka, Y (2019) Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex. Journal of Pharmacological Sciences 140, 197200.CrossRefGoogle ScholarPubMed
Pieczenik, SR and Neustadt, J (2007) Mitochondrial dysfunction and molecular pathways of disease. Experimental and Molecular Pathology 83, 8492.CrossRefGoogle ScholarPubMed
Roberts, RC (2017) Postmortem studies on mitochondria in schizophrenia. Schizophrenia Research 187, 1725.CrossRefGoogle Scholar
Rosebush, PI, Anglin, RE, Rasmussen, S and Mazurek, MF (2017) Mental illness in patients with inherited mitochondrial disorders. Schizophrenia Research 187, 3337.CrossRefGoogle ScholarPubMed
Rosenthal, TC, Majeroni, BA, Pretorius, R and Malik, K (2008) Fatigue: An overview. American Family Physician 78, 11731179.Google ScholarPubMed
Suvisaari, J, Keinänen, J, Eskelinen, S and Mantere, O (2016) Diabetes and schizophrenia. Current Diabetes Reports 16, 110.CrossRefGoogle Scholar
Tardy, AL, Pouteau, E, Marquez, D, Yilmaz, C and Scholey, A (2020) Vitamins and minerals for energy, fatigue and cognition: A narrative review of the biochemical and clinical evidence. Nutrients 12, pii:E228.CrossRefGoogle ScholarPubMed
Torrell, H, Alonso, Y, Garrabou, G, Mulet, D, Catalán, M, Valiente-Pallejà, A, Carreño-Gago, L, García-Arumí, E, Montaña, E, Vilella, E and Martorell, L (2017) Mitochondrial dysfunction in a family with psychosis and chronic fatigue syndrome. Mitochondrion 34, 18.CrossRefGoogle Scholar
Valiente-Pallejà, A, Torrell, H, Muntané, G, Cortés, MJ, Martínez-Leal, R, Abasolo, N, Alonso, Y, Vilella, E and Martorell, L (2018) Genetic and clinical evidence of mitochondrial dysfunction in autism spectrum disorder and intellectual disability. Human Molecular Genetics 27, 891900.CrossRefGoogle ScholarPubMed
Verge, B, Alonso, Y, Miralles, C, Valero, J, Vilella, E, Boles, RG, Martorell, L (2012) New Evidence for the Involvement of Mitochondrial Inheritance in Schizophrenia. Journal of Clinical Psychiatry 73, 684690.CrossRefGoogle Scholar
Virtanen, T, Eskelinen, S, Sailas, E and Suvisaari, J (2017) Dyspepsia and constipation in patients with schizophrenia spectrum disorders. Nordic Journal of Psychiatry 71, 4854.CrossRefGoogle ScholarPubMed
Wallace, DC (2017) A Mitochondrial Etiology of Neuropsychiatric Disorders. JAMA Psychiatry 74, 863864.CrossRefGoogle ScholarPubMed
Waters, F, Naik, N and Rock, D (2013) Sleep, fatigue, and functional health in psychotic patients. Schizophrenia Research and Treatment 2013, 425826.CrossRefGoogle ScholarPubMed